Summary

Eligibility
for people ages 18-60 (full criteria)
Location
at Los Angeles, California and other locations
Dates
study started
completion around
Principal Investigator
by Anjay Rastogi, MD, PhD
Headshot of Anjay Rastogi
Anjay Rastogi

Description

Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of VX-147 in participants aged 18 years and older with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Official Title

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease

Keywords

Proteinuric Kidney Disease, Kidney Diseases, VX-147

Eligibility

You can join if…

Open to people ages 18-60

You CAN'T join if...

Other protocol defined Inclusion/Exclusion criteria apply.

Locations

  • UCLA Division of Nephrology completed
    Los Angeles California 90095 United States
  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center accepting new patients
    Torrance California 90502 United States
  • Cedars-Sinai Medical Center accepting new patients
    Los Angeles California 90048 United States
  • Kaiser Permanente - Los Angeles Medical Center accepting new patients
    Los Angeles California 90027 United States
  • Amicis Research Center accepting new patients
    Granada Hills California 91344 United States
  • Renal Consultants Medical Group accepting new patients
    Granada Hills California 91344 United States
  • Eastside Clinical Research Associates accepting new patients
    Los Angeles California 90022 United States

Lead Scientist at UCLA

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Vertex Pharmaceuticals Incorporated
Links
Sign up for this study
ID
NCT05312879
Phase
Phase 3 Kidney Disease Research Study
Study Type
Interventional
Participants
Expecting 466 study participants
Last Updated